Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3676-3690

  Shinoda, Kaori ^a   Xin, Ke Qin ^a   Jounai, Nao ^a   Kojima, Yoshitsugu ^a   Tamura, Yuichi ^a   Okada, Eiichi ^a   Kawamoto, Susumu ^a   Okuda, Katsuji ^b   Klinman, Dennis ^c   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c Center for Biologics Evaluation/Res   (United States)

Author keywords

HIV 1; Multivalent poly epitope vaccine; Vaccination

Indexed keywords

ARGINYLLEUCYLISOLEUCYLASPARTYLLEUCYLLEUCYLLEUCYLISOLEUCYLALANYLLYSYL ARGININE; DNA VACCINE; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCYLGLUTAMYLISOLEUCYLTYROSYLLYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYL LEUCYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUCYLVALYLARGINYLMETHIONYLTYROSYLSERYL PROLINE; HISTIDYLCYSTEINYLGLUTAMINYLVALYLCYSTEINYLPHENYLALANYLMETHIONYLTHREONYL LYSYLGLYCYLLEUCYLGLYCYLISOLEUCYLSERYLTYROSYLGLYCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYSYLISOLEUCYLARGINYLLEUCYLARGINYLPROLYLGLYCYLGLYCYLASPARAGINYLLYSYLLYSYL TYROSYLLYSYLLEUCYLLYSINE; LYSYLSERYLISOLEUCYLARGINYLISOLEUCYLGLYCYLPROLYLGLYCYLGLUTAMINYLTHREONYL PHENYLALANYLTYROSYLALANINE; LYSYLSERYLISOLEUCYLARGINYLISOLEUCYLGLYCYLPROLYLGLYCYLGLUTAMINYLTHREONYL PHENYLALANYLTYROSYLALANYLLYSYLSERYLVALYLARGINYLISOLEUCYLGLYCYLPROLYLGLYCYL ARGINYLVALYLLEUCYLTYROSYLTHREONINE; LYSYLSERYLVALYLARGINYLISOLEUCYLGLYCYLPROLYLGLYCYLARGINYLVALYLLEUCYLTYROSYL THREONINE; PHENYLALANYLPROLYLVALYLARGINYLPROLYLGLUTAMINYLVALYLPROLYLLEUCYLARGINYL PROLYLMETHIONYLTHREONYLTYROSYLLYSINE; POL PROTEIN; SERYLPHENYLALANYLASPARAGINYLCYSTEINYLGLYCYLGLYCYLGLUTAMYLPHENYLALANYL PHENYLALANYLTYROSYLCYSTEINYLASPARAGINYLSERINE; SERYLPROLYLALANYLISOLEUCYLPHENYLALANYLGLUTAMINYLSERYLSERYLMETHIONYL THREONYLLYSINE; SYNTHETIC PEPTIDE; THREONYLARGINYLLYSYLARGINYLISOLEUCYLARGINYLISOLEUCYLGLUTAMINYLARGINYL GLYCYLPROLYLGLYCYLARGINYLALANYLPHENYLALANYLVALYLTHREONYLISOLEUCYLGLYCINE; THREONYLSERYLISOLEUCYLTHREONYLISOLEUCYLGLYCYLPROLYLGLYCYLGLUTAMINYLVALYL PHENYLALANYLTYROSYLARGININE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VALYLGLUTAMYLARGINYLTYROSYLLEUCYLLYSYLASPARTYLGLUTAMINYLGLUTAMINYLLEUCYL LEUCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVATION; CODON; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; ENVELOPE GENE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS STRAIN; VIRUS TITRATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HYPERSENSITIVITY, DELAYED; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMIDS; PROMOTER REGIONS (GENETICS); T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 4143068079     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.015     Document Type: Article

References (60)

1. Okuda K., Bukawa H., Hamajima K., Kawamoto S., Sekigawa K., Yamada Y., et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Hum Retroviruses. 11(8):1995;933-943
2. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 11(9):1993;957-960
3. Ulmer J., Donnelly J., Parker S., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259(5102):1993;1745-1749
4. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science. 247(4949 Pt 1):1990;1465-1468
5. Sasaki S., Inamura K., Okuda K. Genes that induce immunity-DNA vaccines. Microbiol. Immunol. 43(3):1999;191-200
6. Wang B., Ugen K.E., Srikantan V., Agadjanyan M.G., Dang K., Refaeli Y., et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1as. Proc. Natl. Acad. Sci. U.S.A. 90(9):1993;4156-4160
7. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209(1):1995;147-154
8. Bukawa H., Sekigawa K., Hamajima K., Fukushima J., Yamada Y., Kiyono H., et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1(7):1995;681-685
9. Ciernik I.F., Krayenbuhl B.H., Carbone D.P. Puncture-mediated gene transfer to the skin. Hum Gene. Ther. 7(8):1996;893-899
10. Korber B, Brander C, Haynes B, Koup R, Kuiken C, Moore J, et al., HIV molecular immunology. Los Alamos, NM: Los Alamos National Laboratory; 2000.
11. Liu W.J., Zhao K.N., Gao F.G., Leggatt G.R., Fernando G., Frazer I.H. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine. 20(5-6):2001;862-869
12. Narum D.L., Kumar S., Rogers W.O., Fuhrmann S.R., Liang H., Oakley M., et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun. 69(12):2001;7250-7253
13. Deml L., Bojak A., Steck S., Graf M., Wild J., Schilmbeck R., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75(22):2001;10991-11001
14. Egan M.A., Charini W.A., Kuroda M.J., Schmitz J.E., Racz P., Tenner-Racz K., et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J. Virol. 74(16):2000;7485-7495
15. zur Megede J., Chen M.-C., Doe B., Schaefer M., Greer C.E., Selby M., et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74(6):2000;2628-2635
16. Uchijima M., Yoshida A., Nagata T., Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol. 161(10):1998;5594-5599
17. Schneider R., Campbell M., Nasioulas G., Felber B.K., Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71(7):1997;4892-4903
18. Hentze M. Determinants and regulation of cytoplasmic mRNA stability in eukaryotic cells. Biochim. Biophys. Acta. 1090(3):1991;281-292
19. Berzofsky J.A. Designing peptide vaccines to broaden recognition and enhance potency. Ann N Y Acad. Sci. 754:1995;161-168
20. De Groot A.S., Clerici M., Hosmalin A., Hughes S.H., Barnd D., Hendrix C.W., et al. Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope. J. Infect Dis. 164(6):1991;1058-1065
21. Kim J.E., Kojima M., Houghten R., Pendleton C.D., Cornette J.L., Delisi C., et al. Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type. Mol. Immunol. 27(10):1990;941-946
22. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108(2):1991;193-199
23. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 12(2):1984;857-872
24. Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl P., Moss B., et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA. 95(4):1998;1709-1714
25. Liu L., Watabe S., Yang J., Hamajima K., Ishii N., Hagiwara E., et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine. 20(1-2):2001;42-48
26. Tsuji T., Hamajima K., Fukushima J., Xin K.-Q., Ishii N., Aoki I., et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12as. J. Immunol. 158(8):1997;4008-4013
27. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA. 97(8):2000;4192-4197
28. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161(4):1998;1875-1882
29. Landolfi N.F. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J. Immunol. 146(3):1991;915-919
30. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 123(1):1979;182-188
31. Thorne P.S. Inhalation toxicology models of endotoxin- and bioaerosol-induced inflammation. Toxicology. 152(1-3):2000;13-23
32. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62(10):1988;3779-3788
33. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159(7):1997;3638-3647
34. Toda S., Ishii N., Okada E., Kusakabe K.-I., Arai H., Hamajima K., et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-γ antibody. Immunology. 92(1):1997;111-117
35. Yu J., Cassels F., Scharton-Kersten T., Hammond S.A., Hartman A., Angov E., et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun. 70(3):2002;1056-1068
36. Chen D., Periwal S.B., Larrivee K., Zuleger C., Erickson C.A., Endres R.L., et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75(17):2001;7956-7965
37. Hagiya M., Davis D.D., Takahashi T., Okuda K., Raschke W.C., Sakano H. Two types of immunoglobulin-negative Abelson murine leukemia virus-transformed cells: implications for B-lymphocyte differentiation. Proc. Natl. Acad. Sci. USA. 83(1):1986;145-149
38. Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997;(2):141-52.
39. Beekman N.J., van Veelen P.A., van Hall T., Neisig A., Sijts A., Camps M., et al. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J. Immunol. 164(4):2000;1898-1905
40. Lucchiari-Hartz M., van Endert P.M., Lauvau G., Maier R., Meyerhans A., Mann D., et al. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J. Exp. Med. 191(2):2000;239-252
41. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. J Virol 1990;179(1):247-66, 517-63.
42. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17:1999;739-779
43. Nussbaum A.K., Kuttler C., Hadeler K.-P., Rammensee H.-G., Schild H. PAProC: a prediction algorithmfor proteasomal cleavages available on the WWW. Immunogen. 53(2):2001;87-97
44. Neisig A., Roelse J., Sijts A.J., Ossendorp F., Feltkamp M.C., Kast W.M., et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154(3):1995;1273-1279
45. Niedermann G., Butz S., Ihlenfeldt H.G., Grimm R., Lucchiari M., Hoschutzky H., et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity. 2(3):1995;289-299
46. Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157(2):1996;822-826
47. Thomson S.A., Khanna R., Gardner J., Burows S.R., Coupar B., Moss D.J., et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA. 92(13):1995;5845-5849
48. Loirat D., Lemonnier F.A., Michel M.L. Multiepitopic HLA-A*0201- restricted immune response against hepatitis B surface antigen after DNA-based immunization. J. Immunol. 165(8):2000;4748-4755
49. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., et al. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 73(7):1999;5320-5325
50. Ahlers J.D., Pendleton C.D., Dunlop N., Minassian A., Nara P.L., Berzofsky J.A. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150(12):1993;5647-5665
51. Dai Z., Konieczny B.T., Lakkis F.G. The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J. Immunol. 165(6):2000;3031-3036
52. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150(2):1993;635-643
53. Juvier-Maurin V., Saragosti S., Perret J.L., Mpoudi E., Esu-Williams E., Mulanga C., et al. Genetic characterization of the nef gene from human immunodeficiency virus type 1 group M strains representing genetic subtypes A, B, C, E, F, G, and H. AIDS Res. Hum Retroviruses. 15(1):1999;23-32
54. Ranki A., Suni J., Blazevic V., Holmstrom P., Mattinen S., Krohn K., et al. T-cell recognition of HIV antigens in HIV-seroreverted persons. AIDS. 11(1):1997;132-133
55. Wolinsky S.M., Korber B.T., Neumann A.U., Daniels M., Kunstman K.J., Whetsell A.J., et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 272(5261):1996;537-542
56. Dadaglio G., Leroux A., Langlade-Demoyen P., Bahraoni E.M., Traincard F., Fisher R., et al. Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. J. Immunol. 147(7):1991;2302-2309
57. Jassoy C., Harrer T., Rosenthal T., Navia B.A., Worth J., Johnson R.P., et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon. J. Virol. 67(5):1993;2844-2852
58. Betts M.R., Casazza J.P., Patterson B.A., Waldrop S., Trigona W., Fu T.M., et al. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J. Virol. 74(19):2000;9144-9151
59. Klenerman P., Rowland-Jones S., McAdam S., Edwards J., Daenke S., Lalloo D., et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 369(6479):1994;403-407
60. Hay C.M., Ruhl D.J., Basgoz N.O., Wilson C.C., Billingsley J.M., De Pasquale M.P., et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J. Virol. 73(7):1999;5509-5519